Imalumab

{{Short description|Monoclonal antibody}}

{{Infobox drug

| type = mab

| image =

| alt =

| mab_type =

| source =

| target =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status = Investigational

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action=

| excretion =

| CAS_number = 1430205-07-4

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| UNII = 22F97PC79G

| synonyms = BAX69

}}

Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.{{cite book | doi = 10.1158/1535-7163.TARG-15-A153 | chapter = Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (OxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients | title = Therapeutic Agents: Biological | pages = A153 | year = 2015 | vauthors = Douillard P, Thiele M, Schinagl A, Halama N, Jaeger D, Yazji S, Scheiflinger F, Kerschbaumer R | journal = Molecular Cancer Therapeutics | volume = 14 | issue = 12_Supplement_2 }}{{ClinicalTrialsGov|NCT02448810|Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer}}{{ClinicalTrialsGov|NCT01765790|Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumor}} and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.{{cite web | url=http://adisinsight.springer.com/drugs/800010225 |title = Imalumab | work = AdisInsight | publisher = Springer Nature Switzerland AG }}

A phase I/II trial in patients with malignant ascites was terminated in 2016.